Liver Diseases  >>  deleobuvir (BI 207127)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
deleobuvir (BI 207127) / Boehringer Ingelheim
NCT02176525: Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

Completed
1
75
Europe
BI 207127 NA, Placebo
Boehringer Ingelheim
Hepatitis C, Chronic
12/09
 
NCT00905632: 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Completed
1
75
Europe
BI 207127 middle dose +SOC, BI 207127 high dose+SOC, Placebo + SOC, BI 207127 low dose + SOC
Boehringer Ingelheim
Hepatitis C, Chronic
03/11
 
NCT01525628: Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Completed
1
72
US, Canada, Europe
midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
Boehringer Ingelheim
Hepatitis C, Chronic
12/13
10/14

Download Options